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Background: Accumulating evidence suggests that hyperactivity of the hypothalamic-pituitary-
adrenal axis (HPA axis) is involved in depression. 11-Hydroxysteroid dehydrogenase type 1 (11-
HSD1) converts inert cortisone to active cortisol and is implicated in HPA axis regulation in animal
studies. The aim of our study was to identify polymorphisms in 11-HSD1 gene (HSD11B1) with
consistent associations with increased HPA axis activity and relate those polymorphisms to
depression.
Methods: Twelve single-nucleotide polymorphisms (SNPs), including 11 tagging SNPs, were se-
lected using the HapMap database and genotyped in 4228 participants of the population-based
RotterdamStudy.Theoutcomemeasureswere salivary cortisol levelsafterawakening,30min later,
at 1700 h, at bedtime, and plasma levels of androstenedione (in women only). SNPs that were
significantly associatedwith cortisol aswell as androstenedione levelswere also related to incident
depression.
Results: rs11119328was associatedwith higher cortisol saliva samples collected at bedtime as well
as higher androstenedione levels (P value after correction for multiple testing: 0.01 and 0.04, respec-
tively). Carriersof thispolymorphismhadan increased riskofan incidentdepression (hazard ratio1.28,
95% confidence interval 1.03–1.59). Two other SNPs, which were in high linkage disequilibriumwith
rs11119328, were related to higher cortisol levels but not with androstenedione levels.
Conclusions:We identified one SNP, which was associated with increased salivary cortisol levels at
nadiraswell ashigherandrostenedione levels.Moreover, this SNPwasalsoassociatedwithahigher
risk of an incident depression. This suggests that 11-HSD1 is implicated in human HPA axis reg-
ulation and susceptibility to depression. (J Clin Endocrinol Metab 97: E233–E237, 2012)
Glucocorticoids are centrally regulated by the nega-tive feedback action of the hypothalamic-pitu-
itary-adrenal (HPA) axis: cortisol inhibits proopiomel-
anocortin gene transcription in the anterior pituitary
andCRHgene transcription and peptide secretion in the
hypothalamus (1). Local, tissue-specific cortisol con-
centrations are fine-tuned by two enzymes, 11-hy-
droxysteroid dehydrogenase type 1 (11-HSD1) and
11-hydroxysteroid dehydrogenase type 2. In vivo,
11-HSD1 converts cortisone to cortisol, whereas 11-
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hydroxysteroid dehydrogenase type 2 converts cortisol
to cortisone (2).
Animal studies strongly suggest that 11-HSD1 also
plays a role in central HPA axis regulation. In rodents,
11-HSD1 expression is observed in the anterior pitu-
itary, the paraventricular nucleus (PVN), and the hip-
pocampus (2–4). Furthermore, 11-HSD1-deficient mice
showed elevated basal corticosterone and ACTH levels
and exaggerated ACTH and corticosterone responses to
restraint stress, suggesting diminished glucocorticoid
feedback (5).
In the present study, we evaluated the associations of
common genetic variation in HSD11B1 with HPA axis
activity using a tagging single-nucleotide polymorphism
(SNP) approach. As markers for HPA axis activity, we
used salivary cortisol levels and in women also adrenal
androgens. Our aim was to identify SNP that show con-
sistent associations with increased HPA axis activity and
relate those polymorphisms to incident depression.To test
these hypotheses,weuseddata from theRotterdamStudy,
a population-based cohort study in an elderly population.
Materials and Methods
Study population
The present study was embedded in the Rotterdam Study,
an ongoing population-based cohort study of persons aged 55
yr and older (6). So far, four study surveys have taken place in
which participants underwent differentmeasurements. A time
line of these study surveys is given in Supplemental Fig. 1,
published on The Endocrine Society’s Journals Online web
site at http://jcem.endojournals.org.
Plasma androstenedione measurement
Analyses with androstenedione were performed in women
only because in postmenopausal women the adrenals are the
main source of androgen production, and its release is under the
control of the HPA axis. In a limited number of women who
participated in the baseline examinations (1990–1993, n 
883), plasma levels of androstenedione were determined as de-
scribed previously (7). Androstenedione is stable in frozen
plasma (8). Women using exogenous hormones (n  39) were
excluded. This resulted in a study population of 844 women.
Salivary cortisol
During the fourth study, survey (2002–2004) participants
collected saliva samples at four different time points: directly
after awakening, 30 min later, at 1700 h, and at bedtime
(Cortbed). Details on saliva collection and cortisolmeasurements
have been described previously (9). For each time point, cortisol
values that were above the 98th percentile were excluded. This
conservative cutoff was chosen due to the high number of out-
liers, in linewith earlier studies (9).Moreover, the98thpercentile
of late-night salivary cortisol levels (13.4 nmol/liter) corre-
sponded approximately to the cutoff value used in the diagnosis
of Cushing’s syndrome. Persons using systemic glucocorticoids
(n  49) were excluded. This resulted in a study population of
2190 participants.
Incident depression
Depression screening followed a multistep protocol and has
been described in detail previously (10). In short, screening for
depression had started during the second study round (1993–
1995) using standardized questionnaires. Information on the oc-
currence of depressions during follow-up was obtained from
psychiatric examinations during the examination rounds, self-
reported histories of depression, medical records, and registra-
tion of antidepressant use via an automatic link with the phar-
macies that serves the study area. An event was considered a
depressive syndrome if one of the following conditions was met:
aDiagnostic andStatisticalManual ofMentalDisorders-defined
major or minor depression diagnosed by a psychiatrist or an-
othermental health professional, depressions recorded by a gen-
eral practitioner (GP) or other physician, and a self-reported
depression for which the participant consulted a GP or a mental
health professional.Wedefined the date of onset as the dayof the
first report of symptoms or the first prescription date of an an-
tidepressant drug, whichever came first.
At baseline (second study round), we excluded 549 persons
with depressive symptoms, 105with dementia, ninewith bipolar
disorder, and two lost to follow-up directly after screening. This
resulted in a study population of 4228 persons.
DNA analysis
HSD11B1 tagging SNPs were selected using the HapMap
database (public release no. 20). SNPs were selected to tag com-
mon variation (allele frequency cutoff 5%) 5 kb upstream and 1
kb downstreamofHSD11B1. This resulted in the selection of 11
tagging SNPs. Because HSD11B1 83,557insA (rs45487298),
which is in full linkage disequilibrium (LD) with a TG substi-
tution at position 83,597 (rs12086634), has been extensively
studied previously, we also included this polymorphism in our
analyses.
The appropriate Assay-by-Design mixes were obtained from
Applied Biosystems (Foster City, CA). See Supplemental Table 1
for primer sequences. Plates were analyzed using the Applied
Biosystems 7900HT sequence detection system and sequence
detection system version 2.0 software (Applied Biosystems). To
confirm the accuracy of genotyping results, 5% of the samples
were regenotyped. Percentage of concordance was higher than
99% for all SNPs.
Statistical analyses
Hardy-Weinberg equilibria were calculated using 2 analy-
ses.Haploview (release 4.1)was used todetermine theLDblocks
and the r2 values. All hormone levels were log transformed to
normalize distributions.
First, linear regression models were used to study the effects
of HSD11B1 SNPs on hormonal measures. P values were cor-
rected for multiple testing using a permutation procedure
(10,000 permutations) available in theRpackageGenABEL ver-
sion 1.6–4 (11).Next, we studied the effectsHSD11B1 SNPs on
the incidence of depressive disorder using proportional hazard
analyses. To minimize multiple testing, only SNP that were as-
sociated with higher salivary cortisol as well as higher andro-
stenedione levels were included in these analyses. Subjects were
analyzed as carriers (one or two copies of minor allele) vs. non-
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carriers. All analyses were adjusted for age and sex. Statistical
analyses were performed using SPSS for Windows, release 15.0
(SPSS Inc., Chicago, IL). Post hoc analyses were performed to
study the effect ofHSD11B1 SNPsonhormonal levels in persons
without a history of depression.
Results
Figure 1 shows a schematic overviewofHSD11B1 and the
selected SNPs. Additional SNP information is provided in
Supplemental Table 2 and Supplemental Fig. 2. Popula-
tion characteristics are given in Supplemental Table 3.
Of the12SNPs, onlyoneSNP, rs11119328, showedcon-
sistent associations with higher levels of salivary cortisol at
bedtime as well as androstenedione in women (Table 1).
These associations remained statistically significant after
correctionformultiple testing.TwootherSNPs,rs11487867
and rs45487298, which are in high LD with rs11119328
(Supplemental Fig. 2), were significantly associated with
higher salivary cortisol at bedtime but not
with androstenedione (Table 1). None of
the analyses with other HSD11B1 SNPs
andhormonalmeasures reached statistical
significance.
Post hoc analyses showed that
rs11119328 was also associated with
higher Cortbed levels in persons with-
out a history of depression at the fourth
study survey (n  1121, BCort(bed) 
0.056 Lognmol/liter [95% confidence in-
terval (CI) 0.015–0.097 Lognmol/liter),
P 0.007]. A similar trend was not ob-
served for androstenedione after exclu-
sion of persons with a history of depres-
sion [n  251, B  0.006 Lognmol/liter
(95% CI 0.027–0.066 Lognmol/liter),
P 0.414].
We used Cox proportional hazard analyses to study
the effect ofHSD11B1 SNPs on incidence of depression.
For these analyses only one SNP, rs11119328, which
was associated with higher Cortbed as well as higher
androstenedione levels, was selected. Carriers of rs11119328
had a significantly higher chance of having an incident
depressive syndrome: hazard ratio 1.28, 95% CI 1.03–
1.59. Follow-up time consisted of 35413 person-years,
with a mean follow-up time of 8.4 yr per subject. A total
of 351 subjects were diagnosed with an incident depres-
sive syndrome.
Discussion
The present study shows that a common genetic variant in
HSD11B1, rs11119328, is associated with higher late-
night salivary cortisol levels and in postmenopausal
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FIG. 1. Schematic overview of HSD11B1, selected tagging SNPs, and minor allele frequencies
(MAF).
TABLE 1. Associations of HSD11B1 SNPs and adrenal hormone levels
rs11119328 rs11487867 rs45487298
 (95% CI)a P valuea
Pcorrected
valueb  (95% CI)a P valuea
Pcorrected
valueb  (95% CI)a P valuea
Pcorrected
valueb
Cortisol measures (n  2190)c
Cortaw, Lognmol/liter 0.004 (0.021 to 0.028) 0.78 1 0.006 (0.018 to 0.030) 0.63 0.99 0.010 (0.012 to 0.033) 0.38 0.98
Cortaw  30, Lognmol/liter 0.028 (0.005 to 0.051) 0.02 0.16 0.017 (0.006 to 0.039) 0.15 0.73 0.020 (0.001 to 0.042) 0.07 0.44
Cort1700 h, Lognmol/liter 0.027 (0.002 to 0.053) 0.03 0.27 0.029 (0.005 to 0.054) 0.02 0.18 0.030 (0.007 to 0.054) 0.01 0.10
Cortbed, Lognmol/liter 0.049 (0.019 to 0.080) 0.001 0.01 0.044 (0.014 to 0.073) 0.004 0.04 0.044 (0.016 to 0.072) 0.002 0.02
Adrenal androgen (n  844)c
Androstenedione, Lognmol/liter 0.039 (0.012 to 0.067) 0.005 0.04 0.016 (0.010 to 0.042) 0.23 0.87 0.024 (0.001 to 0.050) 0.06 0.41
Cortaw, Cortisol saliva samples collected directly after awakening; Cortaw30, cortisol saliva samples collected 30 min later; Cort1700 h, cortisol saliva
samples collected at 1700 h.
a Values represent  -coefficients, 95% CI, and P values adjusted for age and sex (cortisol measures) or age (androstenedione).
b P value additionally corrected for multiple testing by permutation analyses.
c Numbers differ slightly between analyses due to differences in genotype success rates between SNPs and differences in number of available saliva
samples at different time points. Please note that values represent log-transformed hormonal levels. Mean untransformed and log-transformed
hormonal values are given in Supplemental Table 3.
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womenwithhigher androstenedione levels.This polymor-
phism was also related to an increased susceptibility to
depression. Two other HSD11B1 SNPs, which were in
high LD with rs11119328, were related to higher cortisol
levels but not with androstenedione levels.
Several observations support the concept that 11-
HSD1 plays an important role in HPA axis regulation. In
rodents, 11-HSD1 is highly expressed at the central feed-
back sites of the HPA axis (2–4). Harris et al. (5) showed
that 129/MF1 mice lacking 11-HSD1 activity show ele-
vated basal corticosterone and ACTH levels and exagger-
ated ACTH and corticosterone responses to restraint
stress, suggesting diminished glucocorticoid feedback. In
our study we found an association between rs11119328
and increased measures of HPA axis activity at two dif-
ferent points in time: higher cortisol levels at nadir (mea-
sured 1990–1993) as well as higher androstenedione lev-
els (measured 2002–2004), indicating a higher set point of
the HPA axis. One possible explanation is that this SNP is
associatedwith lower expression of 11-HSD1 at the cen-
tral feedback sitesof theHPAaxisorperipherally resulting
in diminished negative feedback.
Diminished HPA axis negative feedback is thought to
be a key element in depressive disorder neurobiology. So
far, it is not yet clear whether these changes in HPA axis
function are consequences of central neurotransmitter
changes occurring during depression. Or, alternatively,
that increased HPA axis activity plays a causal role in the
etiologyofdepression.Our studywasnotdesigned to infer
causality between HPA axis activity and depression.
Therefore, the observed association between rs11119328
and depression might be the result of increased HPA axis
activity or, alternatively, the observed increasedhormonal
levels might the result of a previous depression. Post hoc
analyses showed that rs11119328 was also associated
with higher Cortbed levels in persons without a history of
depression, suggesting that this association is not the result
of a previous depressive episode.However, a similar trend
was not observed for androstenedione.
Some other methodological issues of our study need to
be discussed. First, studies using saliva sampling to deter-
mine the diurnal cortisol pattern rely heavily upon par-
ticipant compliance.Kudielka et al. (12) showed in a study
with electronic monitoring devices that a significant num-
ber of participants in an ambulatory setting did not obtain
saliva samples reliably. Themost important effect of com-
pliance on the cortisol measurement was seen for the cor-
tisol awakening response. Compliant subjects showed a
robust increase in cortisol values 30 min after awakening,
whereas participants who failed to obtain this sample at
the correct timing only showed minimal changes from
baseline. The influence of variation in sampling time is
much smaller for evening cortisol levels because these lev-
els are more stable. Noncompliance to the study protocol
has probably also influenced the salivary cortisol concen-
trations in our study. Thismight explain the negative find-
ings for the relationship between HSD11B1 SNPs and
morning cortisol levels.
Second, genetic association studies are prone to both
type 1 and type 2 errors. Large numbers of subjects are
needed because effect sizes for common variants are typ-
icallymodest (13, 14).Our studywas designed to evaluate
the effects of HSD11B1 SNPs on salivary cortisol mea-
sures (n 2190) and depression (n 4228). Possibly our
studywas underpowered todetect significant effects of the
two SNPs that are in strong LD with rs11119328
(rs11487867 and rs45487298) on androstenedione levels
(n  844). Also, multiple testing is an issue, and we ad-
justed for this by using permutation analyses. However,
replication studies are the golden standard and future
studies are needed to confirm our results.
In summary, we showed that one tagging SNP in
HSD11B1, rs11119328, is associated with increased late-
night cortisol levels and in postmenopausal women with
higher androstenedione levels. Carriers of this polymor-
phism are also at increased risk of developing a depressive
episode. These findings suggest that 11-HSD1 is impli-
cated in human HPA axis regulation and depressive dis-
order neurobiology.
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